How Uzoamaka Clara Bokolo Is Engineering New Weapons Against Drug-Resistant Infections

By Tosin Clegg

When Uzoamaka Clara Bokolo left Nigeria for doctoral studies at the University of Toledo, Ohio, she carried with her a research agenda shaped by an urgent reality: the bacteria and viruses that kill the most people are increasingly the ones science is least equipped to stop. Antibiotic resistance is eroding the effectiveness of frontline treatments. Viral haemorrhagic fevers like Hantavirus remain without approved therapies. Bokolo, a top-graduating alumna of Niger Delta University and a recipient of the EducationUSA Opportunity Funds Programme, has positioned her doctoral research directly at these gaps — work funded by the National Institutes of Health through the National Institute of Allergy and Infectious Diseases (NIH/NIAID), deploying carbohydrate chemistry, bioconjugation, and small-molecule drug design to build tools that medicine currently lacks.
Her most developed line of work centres on Pseudomonas aeruginosa — a gram-negative opportunistic pathogen and one of the leading causes of hospital-acquired infections globally, particularly dangerous in immunocompromised patients and those with cystic fibrosis or burn wounds. What makes it especially formidable is its capacity to form biofilms and acquire resistance to multiple antibiotic classes simultaneously. Bokolo has tackled this through vaccine chemistry rather than antibiotics, focusing on the Psl exopolysaccharide, a surface polysaccharide that plays a central role in P. aeruginosa. On a polymer-supported synthetic platform, she designed and executed the stepwise assembly of the Psl pentasaccharide unit, carefully optimising each glycosylation step for yield and purity. The goal is a conjugate vaccine — one that links this chemically defined oligosaccharide to the carrier protein CRM197 to generate a targeted immune response against the bacterium’s own surface armour. The candidate is currently under ongoing evaluation, with the potential to offer protection precisely where conventional antibiotics are increasingly failing.
Alongside her bacterial vaccine work, Bokolo has been developing small-molecule inhibitors targeting Hantavirus — a zoonotic pathogen responsible for haemorrhagic fever syndromes with fatality rates reaching 40 percent in certain strains, yet without a single approved antiviral treatment to date. Her approach targets the viral endonuclease, an enzyme essential for Hantavirus replication, using a library of synthesised hydroxypyrimidinone-based derivatives. Each compound was systematically characterised and evaluated through structure-activity relationship analysis, with iterative optimisation aimed at identifying candidates with the potency and selectivity profiles required for further development. In a disease area where therapeutic options are effectively nonexistent, this line of research fills a gap that the scientific community has long acknowledged but not yet resolved.
Bokolo has also taken a multivalent approach to P. aeruginosa vaccination by developing an OprF-PcrV fusion protein candidate that simultaneously targets two of the bacterium’s distinct virulence mechanisms. Her work on this candidate has included adjuvant screening — evaluating combinations such as QS-21 and Pam₃CysSK₄ — and liposomal formulation strategies to enhance immunogenicity. Targeting a single antigen leaves room for bacterial evasion; the dual-target design Bokolo has pursued is intended to make that evasion significantly harder.
Underpinning all of this vaccine work is a methodological contribution that has implications well beyond Bokolo’s own research programme. She has developed a photocleavable linker system for polymer-supported oligosaccharide synthesis — using a pHEMA-based solid support and an o-nitroveratryl-hydroquinone linker responsive to 405 nm light. The system allows complex carbohydrates to be assembled on-resin and then cleanly released by light exposure, eliminating the need for harsh chemical cleavage conditions that can damage sensitive glycan structures. Scalable, controllable, and adaptable, this platform has the potential to streamline the production of polysaccharide vaccine components that currently take significant time and resources to synthesise.
Separate from her doctoral research at Toledo, Bokolo maintains an active research collaboration with colleagues in the Department of Biochemistry at Ebonyi State University, focused on the pharmaceutical potential of Cucumeropsis mannii (egusi) seed oil nano-formulations. The project applies modern pharmaceutical science to a plant with deep roots in West African traditional medicine — characterising its bioactive compounds, standardising the formulation, and investigating how nano-encapsulation can improve bioavailability and expand its therapeutic applications in metabolic and organ health. It is a cross-disciplinary effort that draws on Bokolo’s background in pure and applied chemistry alongside the biochemistry expertise of her collaborating team.
Bokolo has taken her research to national scientific audiences, presenting at the American Chemical Society (ACS) National Meeting, the Midwest Carbohydrate and Glycobiology Symposium, and the Midwest NOBCChE conference. Beyond the laboratory, she has served as a science fair judge at the regional level, reflecting a commitment to scientific mentorship that extends to the next generation of researchers.
The analytical rigour behind her work is supported by proficiency in Nuclear Magnetic Resonance (NMR) spectroscopy, High-Resolution Mass Spectrometry (HRMS), MALDI-TOF, High-Performance Liquid Chromatography (HPLC), and infrared spectroscopy, as well as scientific software including MestReNova. These capabilities allow her to fully characterise each synthesised compound — a non-negotiable standard in research where molecular precision determines whether a drug candidate advances or fails.
Infectious disease medicine is at an inflection point. The drugs that have served for decades are losing ground to resistant organisms, and for some of the world’s most deadly viral infections, no drugs exist at all. Uzoamaka Clara Bokolo is working on both problems simultaneously — synthesising vaccine candidates against a bacterium that routinely defeats antibiotics, and designing inhibitors against a virus that medicine has yet to find an answer for. She brings to this work not just technical skill but a scientific formation shaped by Nigeria, funded by international access programmes, and now operating at the forefront of infectious disease research. The breadth and ambition of what she is building, still at the doctoral stage, points to a career that has only just begun to register its impact.